HIGHER EDUCATION EXPERIENCE Academic

CURRICULUM VITAE

(09/30/14)

DORRAYA EL-ASHRY, Ph.D. Office Phone: (305)243-4721 Current Academic Rank: Associate Professor Primary Department: Department of Internal Medicine,

Division of Hematology/Oncology University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center, Braman Breast Cancer Institute

1550 NW 10th Avenue 410 Pap Miami, Florida 33136

Citizenship: USA HIGHER EDUCATION Undergraduate 08/80 – 05/84 Vanderbilt University, Nashville, TN, B.A. (Molecular Biology, minor in Chemistry) Graduate 08/84 – 02/89 University of Colorado Health Sciences Center, Ph.D.

(Experimental Pathology), Dissertation: A Study on the Cellular and Molecular Properties of Progesterone Receptors in Breast Cancer, directed by Dean P. Edwards

EXPERIENCE Academic 06/1994 – 12/1995 Research Instructor, Dept. of Biochemistry and Molecular Biology,

School of Medicine, Member, Lombardi Cancer Center, Georgetown University, Washington, DC.

01/1996 – 08/1999 Research Assistant Professor, Dept. of Biochemistry and Molecular

Biology, School of Medicine, Member, Lombardi Cancer Center, Georgetown University, Washington, DC.

09/1999 – 06/2000 Research Assistant Professor, Dept. of Oncology and Lombardi Cancer

Center, Georgetown University, Washington, DC. 07/2000 – 08/2001 Assistant Professor, Dept. of Oncology and Lombardi Cancer Center,

Georgetown University, Washington, DC. 09/2001 – 03/2008 Assistant Professor, Dept. of Medicine, Division of

Hematology/Oncology, Member of Cell and Molecular Biology Graduate Program, University of Michigan Health System, Ann Arbor, MI.

Dorraya El-Ashry 10/16/14 1

04/2008 – present Associate Professor, Dept. of Medicine, Division of

Hematology/Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center/Braman Family Breast Cancer Institute, Miami, FL.


PUBLICATIONS PUBLICATIONS - BOOK CHAPTERS and NON-PEER REVIEWED REVIEWS 1. Brinkman J. and El-Ashry, D. ER Re-expression and Re-sensitization to Endocrine Therapies in ER-negative Breast Cancers. J. of Mammary Gland Biol., 14(1):67-78, 2009. 2. Bayliss, J., Hilger, A., Vishnu, P., Diehl, K., and El-Ashry, D. The Re-Expression of Estrogen Receptor in Estrogen Receptor-Negative Breast Cancer and Restoration of Anti-Estrogen Responses in: Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer : New Molecular Aspects and their Potential as Targets (S Hiscox, JMW Gee, RI Nicholson, eds.), Springer, 2009. 3. El-Ashry, D., and Lippman, M.E. The Molecular Biology of Breast Carcinoma. World Journal of Surgery (Progress Symposium Issue), 18:12-20, 1994. 4. El-Ashry, D., and Lippman, M.E. Growth Factors and Their Receptors in Breast Cancer. Peptide Therapy Index and Review, 6 (3):1-2, 13, 1994. 5. Dickson, R.B., Johnson, M., El-Ashry, D., Shi, Y., Bano, M., Zugmaier, G., Ziff, B., Lippman, M.E. and Chrysogelos, S. Breast Cancer: Influence of Endocrine Hormones, Growth Factors and Genetic Alterations. In: The Underlying Molecular, Cellular and Immunological Factors in Cancer and Aging (S.S. Yang and H.R. Warner, eds.), Plenum Press, New York, 1993. 6. Edwards, D.P., Estes, P.A., Lawler-Heavner, J., and El-Ashry-Stowers, D. Structural and Functional Properties of Progesterone Receptors. In: Steroid Receptors and Disease (Sheridan, Blum, and Trachentberg, eds.), Marcel Dekker, Inc., New York, pp. 121-151, 1988. 7. Edwards, D.P., Estes, P.A., El-Ashry, D., Suba, E., and Lawler-Heavner, J. Immunoaffinity Purification and Structural Analysis of Human Breast Cancer Progesterone Receptors. In: Immunological Approaches to the Diagnosis and Therapy of Breast Cancer (R.L. Ceriani, ed.), Plenum Publishing Corp., pp. 157-168, 1987. PUBLICATIONS – JURIED/REFEREED/PEER REVIEWED 1. Creighton, C., Miller, P., Hermon, T., Slingerland, J., and El-Ashry, D. Generation of a Hyperactive Src Gene Signature that Correlates with Luminal B and Her-2 Overexpressing Breast Cancer. Tobe submitted, October, 2014. 2. Drews-Elger, K., Sandoval-Leon A.C., Gomez-Fernandez C.R., El-Ashry, D.*, and Lippman, M.E.* A Mouse Model for Paget’s Disease of the Nipple. To be submitted, October, 2014. *Co-Senior Authors. 3. Shah, S., Miller, P., Contreras, M. G., Issa, E., and El-Ashry, D. MAPK-Regulated microRNAs Secreted by Basal Breast Cancer CAFs Mediate the Estrogen Receptor Negative Phenotype. Submitted, September, 2014. 4. Picon-Ruiz, M., Pan, C., Drews-Elger, K., Jang, K., Besser, A., Zhao, D., Morata-Tarifa, C., Kim, M., Ince, T., Azzam, D., Wander, S., Wang, B., Ergonul, B., Datar, R., Cote, R., Howard, G., El-Ashry,


D., and Slingerland, J. Adipocyte-Breast Cancer Cell Contact Upregulates Cytokines that Drive Src-Dependent Tumor Progression via SOX2 and miR302b. Submitted, August, 2014. 5. Miller, P., Clarke, J., Koru-Sengul, T., Brinkman, J., and El-Ashry, D. A Novel MAPK microRNA Signature is Independently Predictive of Hormone Therapy Resistance and Poor Disease Outcome in ER- Positive Breast Cancer. Clinical Cancer Research, Accepted with minor revisions, 2014. 6. Drews-Elger, K., Iorns, E., Dias A., Ward T.M., Dean S.J., Clarke J., Miller P., Campion-Flora A., Nava-Rodrigues D., Reis-Filho J.S., Rae J.M., Thomas, D., Berry D., El-Ashry D., and Lippman M.E. Infiltrating S100A8+ Myeloid Cells Promote Metastatic Spread of Human Breast Cancer Growth and Predict Poor Patient Outcome. Breast Cancer Res Treat, In press, 2014. 7. Zhao, D., Pan C., Sun J., Gilbert C., Drews-Elger K., Azzam D., Picon-Ruiz M., Kim M., Ullmer W., El-Ashry D., Creighton C., and Slingerland J. VEGF Drives Cancer Initiating Cells Through VEGFR-2/Stat3 Signaling to Upregulate Myc and Sox2. Oncogene, In press, 2014. 8. Plotkin, A., Volmer C.-H., Wahlestedt C., Ayad N., and El-Ashry D. Transcriptional Repression of ER Through hMAPK-Dependent Histone Deacetylation by Class I HDACs. Breast Cancer Res Treat. Sep; 147(2):249-63, 2014. 9. Drews-Elger, K., Brinkman, J., Miller, P., Shah, S., Harrell, C., da Silva, T., Ao, Z., Schlater, A., Azzam, D., Diehl, K., Thomas, D., Slingerland, J., Perou, C., Lippman, M., and El-Ashry, D. Primary Breast Tumor-Derived Cellular Models: Characterization of Tumorigenic and Metastatic, and Cancer Associated Fibroblast Cultures. Breast Cancer Res Treat. Apr;144(3):503-17, 2014. 10. Azzam, D.J., Drews-Elger, K., Zhao, D., Gilbert, C.A., Picon-Ruiz, M., Ranganathan, P., Han, Xiaoqing, H., Sun, J., Minn, A.J., Pan, C., Wander, S.A., Capobianco, A.J., El-Ashry, D., and Slingerland, J.M. Evidence for a Functional and Molecular Hierarchy in Tumor-Initiating Stem Cells in Triple-Negative Breast Cancer: Relevance to Metastasis and Therapy. EMBO Mol Med, 5(10):1502-1522, 2013. 11. Iorns, E., Drews-Elger, K., Ward, T.M., Dean, S., Clarke, J., El-Ashry, D., and Lippman, M.E. A New Mouse Model for the Study of Human Breast Cancer Metastasis. PlosOne, 7(10):e47995, 2012. 12. Bayraktar, U.D., Kim, T.K., Drews-Elger, K., Benjamin, C., El-Ashry, D., Wieder, E., and Komanduri, K.V. Simultaneous Measurement of ER, Her2, and PhosphoERK1/2 in Breast Cancer Cell Lines by Flow Cytometry. Breast Cancer Research and Treatment, 129(2):623-628, 2011. 13. Teschendorff, A.E., Gomez, S., Arenas, A., El-Ashry, D., Schmidt, M., Gehrmann, M., and Caldas, C. Improved Prognostic Classification of Breast Cancer Defined by Antagonistic Activation Patterns of Immune Response Pathway Modules. BMC Cancer, 10:604-624, 2010. 14. Hnatyszyn, J., Lui, M, Hilger, A., Herbert, L., Gomez-Fernandez, C.R., Jorda, M., Thomas, D., Rae, J.M., El-Ashry, D., and Lippman, M.E. Correlations between GREB1 expression and ER, HER2 status in human breast cancer. Breast Cancer Research and Treatment, 122:371-380, 2009. 15. Bayliss, J.*, Hilger, A.*, Vishnu, P., Diehl, K., and El-Ashry, D. Reversal of the Estrogen-Negative Phenotype and Restoration of Anti-Estrogen Response in Breast Cancer. Clinical Cancer Research, 13: 7029-7036, 2007. * Both authors contributed equally.


16. Creighton, C., Hilger, A., Murthy, S., Rae, J., Chinnaiyan, A., and El-Ashry, D. Activation of MAPK in ERα-positive breast cancer cells in vitro induces an in vivo molecular phenotype of ERα-negative human breast tumors. Cancer Research, 66(7):3903-3911, 2006. 17. Marshall, J.L., Eisenberg, S.G., Johnson, M., Hanfelt, J., Dorr, F.A., El-Ashry, D., Oberst, M., Fuxman, Y., Holmlund, J, and Malik, S. A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 4:268-274, 2004. 18. Dontu, G., El-Ashry, D., and Wicha, M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends in Endocrinology and Metabolism, 15:193-197, 2004. 19. Holloway, J.N.*, Murthy, S.*, and El-Ashry, D. A Cytoplasmic Substrate of MAPK is Responsible for ERα Down-Regulation in Breast Cancer Cells: Role of NFκB. Molecular Endocrinology, 18:1396-1410, 2004. * Both authors contributed equally. 20. Dougherty, M.K., Schumaker, L.M., Jordan, V.C., Welshons, W.V., Curran, E., Ellis, M.J., El-Ashry, D. Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer. Cancer Biology and Therapy, 3:460-467, 2004. 21. Marshall, J.L., Bangalore, N., El-Ashry, D., Fuxman, Y., Johnson, M., Norris, B., Oberst, M., Ness, E., Wojtowicz, S., Bhargava, P., Rizvi, N., Baidas, S., and Hawkins, M. Phase I Study of Prolonged Infusion Bryostatin-1 in Patients with Advanced Malignancies, Cancer Biology and Therapy, 1:409-416, 2002. 22. Oh, A.S.*, Lorant, L.A.*, Holloway, J.N., Miller, D.L., Kern, F.G., and El-Ashry, D. Hyperactivation of MAPK Induces Loss of ER Expression in Breast Cancer Cells, Molecular Endocrinology, 15(8):1344-1359, 2001. * Both authors contributed equally. 23. Nass, S.J., Ferguson, A.T., El-Ashry, D., Nelson, W.G., and Davidson, N.E. Expression of DNA Methyl-Transferase (DMT) and the Cell Cycle in Human Breast Cancer Cells. Oncogene, 18:7453-7461, 1999. 24. Clarke, R., Skaar, T., El-Ashry, D., Leonessa F., and Hilakivi-Clarke, L.A. Use of ERE and Reporter Gene Constructs to Assess Putative Estrogenic Activity. J. Med. Food, 2:127-133, 1999. 25. McLeskey, S.W. Zhang, L., Trock, B.J., Kharbanda, S., Tobias, C.A., El-Ashry, D., Dickson, R.B., and Kern, F.G. Tamoxifen-Resistant FGF-Transfected MCF-7 Cells Are Cross-Resistant In Vivo to the Antiestrogen, ICI 182,780, and Two Aromatase Inhibitors. Clinical Cancer Research, 4:697-711, 1998. 26. El-Ashry, D., Miller, D.L., Kharbanda, S., Lippman, M.E., and Kern, F.G. Constitutive Raf-1 Kinase Activity in Breast Cancer Cells Induces Both Estrogen-Independent Growth and Apoptosis. Oncogene, 15:423-435, 1997. 27. Yarden, R.I., Lauber, A.H., El-Ashry, D., and Chrysogelos, S.A. Bimodal Regulation of EGF Receptor by Estrogen in Breast Cancer Cells. Endocrinology, 137:2739-2747, 1996. 28. El-Ashry, D., Chrysogelos, S.A., Lippman, M.E., and Kern, F.G. Estrogen Induction of TGF-α Is Mediated by an Estrogen Responsive Element Composed of Two Imperfect Palindromes. Journal of Steroid Biochemistry and Molecular Biology, 59:261-269, 1996.


29. Liu, Y., El-Ashry, D., Chen, D., Ding, I.Y.F., and Kern, F.G. MCF-7 Breast Cancer Cells Overexpressing Transfected c-erbB2 Have an In Vitro Growth Advantage in Estrogen-Depleted Conditions and Reduced Estrogen-Dependence and Tamoxifen-Sensitivity In Vivo. Breast Cancer Research and Treatment, 34:97-117, 1995.

30. Miller, D.L., El-Ashry, D., Cheville, A.L., Liu, Y., McLeskey, S.W., and Kern, F.G. Emergence of MCF-7 Cells Overexpressing a Transfected Epidermal Growth Factor Receptor Under Estrogen-Depleted Conditions: Evidence for a Role of EGFR in Breast Cancer Growth and Progression. Cell Growth and Differentiation, 5:1263-1274, 1994.

31. Kuhnel, B., El-Ashry, D., Edwards, D.P., and Nordeen, S.K. Mapping Contacts Between Unpurified Human Progesterone Receptor and the Hormone Response Element of Mouse Mammary Tumor Virus. DNA 8: 703-713, 1989.

32. El-Ashry, D., Onate, S.A., Nordeen, S.K., and Edwards, D.P. Human Progesterone Receptor Complexed with the Antagonist RU 486 Binds to Hormone Response Elements in a Structurally Altered Form. Mol. Endocrinology 3: 1545-1558, 1989. 33. El-Ashry-Stowers, D., Zava, D.T., Speers, W.C., and Edwards, D.P. Imunocytochemical Localization of Progesterone Receptors in Breast Cancer with Anti-Receptor Monoclonal Antibodies. Cancer Research 48: 6462-6474, 1988. 34. Estes, P.A., Suba, E.J., Lawler-Heavner, J., El-Ashry-Stowers, D., Wei, L.L., Toft, D.O., Sullivan, W.P., Horwitz, K.B., and Edwards, D.P. Immunologic Analysis of Human Breast Cancer Progesterone Receptors. 1. Immunoaffinity Purification of Transformed Receptors and Production of Monoclonal Antibodies. Biochemistry 26: 6250-6262, 1987. Other Works, Publications, and Abstracts 1. Hew, K., Miller, P., Sun, J., Wei, Z., Zhang, G., Lu, Y., Mills, G., Slingerland, J., El-Ashry, D., and Simpkins, F. MEK Inhibition Reverses Antiestrogen Resistance in Ovarian Cancer (OVCA) Via Alteration of Cell Cycle Pathways and MAPK/Estrogen Regulated Gene Expression. Marsha Rivken Center for Ovarian Cancer Research/American Association for Cancer Research 10th Biennial Ovarian Cancer Research Symposium, Seattle, WA, September, 2014. Oral Presentation. 2. Plotkin, A., Volmer, C.-H., Ayad, N., and El-Ashry, D. Histone Deacetylation Underlying hMAPK-Induced ER mRNA Repression. American Association for Cancer Research Annual Meeting, San Diego, CA, April, 2014. 3. Shah, S., Miller, P., Issa, E., Drews-Elger, K., and El-Ashry, D. Stromal miRNAs as Mediators of Mitogen Activated Protein Kinase-Induced Estrogen Receptor Repression in Breast Cancer. American Association for Cancer Research – Tumor Microenvironment Special Meeting, San Diego, CA, March, 2014. 4. Miller, P., Lairet, S., and El-Ashry, D. Upregulation of miR-224 in Breast Cancer Exhibiting Hyperactivation of ERK1/2 MAPK Signaling Associates with Repression of Raf Kinase Inhibitory Protein and Poor Clinical Outcome, San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2013.


5. Shah, S., Miller, P., Drews-Elger, K., Brinkman, J., Lairet, S., Steinberg, A., and El-Ashry, D. Cancer Associated Fibroblasts Contribute to the Establishment of ER-Negative Breast Cancer Phenotype Through Secreted Factors and miRNAs, American Association for Cancer Research – Advances in Breast Cancer Special Meeting, San Diego, CA, October, 2013. 6. Drews-Elger, K., Dias, A., Iorns, E., El-Ashry, D., and Lippman, M. Identification of Tumor-Induced Changes in Host Stroma of Xenograft Models of Metastatic Breast Cancer, American Association for Cancer Research – Advances in Breast Cancer Special Meeting, San Diego, CA, October, 2013. 7. Miller, P., Shah, S., Lairet, S., Steinberg, A, Heyn, A., Benito, D., and El-Ashry, D. Co-Culture Induced EMT in Breast Tumor Cells is Mediated Through MAPK Signaling and microRNA Regulation, American Association for Cancer Research Meeting, Washington, DC, April 2013. 8. Drews-Elger, K., Iorns, E. Brinkman, J., Berry, D., Lippman, M., and El-Ashry, D. Metastatic Xenograft Models of Human Estrogen Receptor Negative Breast Cancer Primary Cultures Are Driven by the Recruitment of Myeloid-Derived Suppressor Cells. San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2012. 9. Miller, P. and El-Ashry, D. Hyperactive MAPK Signaling Alters Expression of miR221/222 and miR-30 Families, Which Impacts Multiple Pathways and Contributes to Breast Cancer Aggressiveness and Progression. San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2012. 10. Miller, P., Lairet, S., Clarke, J., Richer, J., and El-Ashry, D. Hyperactive MAPK Dysregulation of microRNAs Contributes to the ER-Negative Phenotype in Breast Cancer. American Association of Cancer Research Meeting, Chicago, IL. April, 2012. 11. Azzam, D., J., Drews-Elger, K., Zhao, D., Ranganathan, P., Capobianco, T., Minn, A.J., Creighton, C., Picon, M., Sun, J., Pan, C., Wander, S.A., El-Ashry, D., Slingerland, J.M. CD44+CD24low+ Progenitors in ER Negative Breast Cancer have Higher Notch1 Activation, Self-renewal, and Chemo-resistance and generate CD44+CD24neg Cells and Tumors that Metastasize, American Association of Cancer Research Meeting, Chicago, IL. April, 2012. 12. Miller, P., Clarke, J., Koru-Sengal, T., Brinkman, J., and El-Ashry, D. A Novel Approach Integrating microRNA and mRNA Signatures of HMAPK Signaling is Highly Predictive of ER- Status and Outcome in Breast Cancer – Role of HMAPK miRNAs in Repression of ER and p27. San Antonio Breast Cancer Symposium, San Antonio, TX, December 2011. 13. Drews-Elger, K., Brinkman, J.A., Dean, S., J., and El-Ashry, D. Characterization of Four ER-Negative Primary Tumor Dissociated Cultures as a Model for the in Vitro and in Vivo Study of Tumorigenesis, Metastasis, and Angiogenesis. San Antonio Breast Cancer Symposium, San Antonio, TX, December 2011. 14. Miller, P., Clarke, J., Koru-Sengul, T., Brinkman, J., and El-Ashry, D. Investigation of a Hyperactive MAPK microRNA Expression Profile Reveals Potential Role for microRNAs in the Generation and Maintenance of the ER- Phenotype in Breast Cancer. American Association of Cancer Research Meeting, Orlando, FL. April, 2011.


15. Drews-Elger, K., Brinkman, J., Schlater, A., Azzam, D., Diehl, K., and El-Ashry, D. Characterization of Primary Cultures Dissociated from Estrogen Receptor Negative Breast Cancer Tumors. American Association of Cancer Research Meeting, Orlando, FL. April, 2011. 16. Miller, P., Clarke, J., Koru-Sengul, T., Brinkman, J., and El-Ashry, D. Identification of a Hyperactive MAPK microRNA Signature in Breast Cancer. Keystone Symposia Meeting: MicroRNAs and Non-coding RNAs in Cancer, Banff, Alberta. February, 2011. 17. Miller, P., Clarke, J., Koru-Sengul, T., Brinkman, J., and El-Ashry, D. MAPK-Mediated Gene Expression in ER-Negative Breast Cancer: Role of miRNAs and Ago2. American Association of Cancer Research Meeting, Washington, DC. April, 2010. 18. Miller, P., Clarke, J., Koru-Sengul, T., Brinkman, J., and El-Ashry, D. Investigating Arognaute-2 as an Intermediary Between Signaling Events and Gene Expression in ER-Negative Breast Cancer. Keystone Symposia Meeting: Nuclear Receptors, Keystone, CO. March, 2010. 19. Brinkman, J., Lu, Y., Koru-Sengul, T., Clarke, J., and El-Ashry, D. Identification of ER Negative Tumors in Which MAPK Restores both ER Expression and Anti-Estrogen Responses. San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2009. 20. Brinkman, J. and El-Ashry, D. Restoration of ER Expression and Anti-Estrogen Responses in ER-Negative Breast Cancer. American Association for Cancer Research Meeting, Denver, CO. April, 2009. 21. Bayliss, J., Reisman, D., and El-Ashry, D. MAPK Regulation of SWI/SNF Mediates ERα Down-Regulation. American Association for Cancer Research Meeting, San Diego, CA. April, 2008. 22. Vishnu, P., Bayliss, J., Hilger, A., Diehl, K., and El-Ashry, D. MAPK Inhibition via MEK, EGFR, or erbB-2 Leads to Return of Estrogen-dependence and Anti-estrogen Response in ERα- Breast Cancer. American Association for Cancer Research Meeting, Los Angelos, CA. 2007. Oral Presentaion. Co-Chair of “Steroid Hormone Signaling, Coregulators and Crosstalk with Growth Factor Pathways” Mini-Symposium and *P. Vishnu was selected as an AACR-AFLEC Scholar-In-Training Award for this abstract. 23. Hilger, A., Bayliss, J., Diehl, K., and El-Ashry, D. Restoration of ER Expression and Anti-Estrogen Response in ER-Negative Breast Cancer. American Association for Cancer Research Meeting, Washington, DC, 2006. Abstract #2934. 24. Creighton, C.J., Hilger, A., Murthy, S., Chinnaiyan, A.M., and El-Ashry, D. An mRNA Signature of MAPK Pathway Activation Distinguishes ERα-Negative from ERα-Positive Breast Tumors. American Association for Cancer Research Meeting, Washington, DC, 2006. Abstract #831. 25. Murthy, S., Hilger, A.M., Bayliss, J.M., and El-Ashry, D. Mechanisms Involved in MAPK Induced Repression of ERα in Breast Cancer Cells. American Association for Cancer Research Meeting, Anaheim, CA, 2005. Abstract #1282. 26. Murthy, S. and El-Ashry, D. Gene expression profiling of breast cancer cells with hyperactive p42/44 MAPK. American Association for Cancer Research Meeting, Orlando, FL, 2004. Abst. # 1475. Oral Presentaion. *S. Murthy was selected as an AACR-Komen Scholar-In-Training Award for this abstract.


27. Murthy, S., Holloway, J.N., and El-Ashry, D. Identification of MAP kinase substrates responsible for the downregulation of ERα in breast cancer cells. American Association for Cancer Research Meeting, Washington, DC, 2003, Abst. # 1953. Oral Presentation. Chair of Steroid and Nuclear Receptor/Growth Factor Signaling Pathways Mini-Symposium. 28. Holloway, J.N., Oh, A.S., Alexander, J., and El-Ashry, D. Mechanisms Underlying the Generation of the Estrogen Receptor α-Negative Phenotype. DOD Breast Cancer Research Program ERA of HOPE Meeting, Orlando, FL, 2002. Abst. # P7-10. *As an FY 92-94 PI, this was an invited presentation. 29. Holloway, J.N., Alexander, J., and El-Ashry, D. A Cytoplasmic Substrate of MAPK is Responsible for Downregulation of ERα in Breast Cancer Cells. DOD Breast Cancer Research Program ERA of HOPE Meeting, Orlando, FL, 2002. Abst. #P7-14. Poster Presentation. 30. Holloway, J.N., Alexander, J., and El-Ashry, D. A Cytoplasmic Substrate of MAPK is Responsible for MAPK-Induced Down-regulation of ERα in Breast Cancer Cells. American Association for Cancer Research Meeting, San Francisco, CA, 2002, Abst. #5332. Poster Presentation. 31. Holloway, J.N., Oh, A.S., and El-Ashry, D. MAPK-Induction of the ER-Negative Phenotype – Role of pp90rsk. American Association for Cancer Research Meeting, New Orleans, LA, 2001, Abst. #1272. Poster Presentation. 32. Dougherty, M.K., Schumaker, L., Jordan, V.C., Curran, E., Welshons, W.V., El-Ashry, D., and Ellis, M.J. Estrogen-Regulated Proliferation Influences Paclitaxel Sensitivity in Breast Cancer. American Association for Cancer Research Meeting, New Orleans, LA, 2001, Abst. #1947. Poster Presentation. 33. Lorant, L.A., Oh, A.S., Kern F.G., and El-Ashry, D. Hyperactivated MAPK Induces the ER-Negative Phenotype. DOD Breast Cancer Research Program ERA of HOPE Meeting, Atlanta, GA, 2000. *As an FY 92-94 PI, invited to give a platform presentation. 34. Oh, A.S., Holloway, J.N., and El-Ashry, D., Increased MAPK Activity in EGFR or erbB-2 Overexpressing MCF-7 Cells Induces Down-Regulation of Estrogen Receptor (ER) Expression. American Association for Cancer Research Meeting, San Francisco, CA, 2000. Abst. #464. Oral Presentation, also co-chair of mini-symposium on Breast Cancer. 35. Wolenski, M., Oh, A.S., Lorant, L.A., Kern, F.G., and El-Ashry, D. Role of Growth Factor Receptor Effector Pathways in Generation of the ER-Negative Phenotype in Breast Cancer. Endocrine Society Annual Meeting, San Diego, CA, 1999, Abst. #P3-276. Poster Presentation. 36. Lorant, L.A., Thomas, S. D., and El-Ashry, D. Constitutive Raf-Induced Loss of ER Expression is Reversible: Is Re-definition of the ER-Negative Phenotype Needed? American Association for Cancer Research Meeting, New Orleans, LA, 1998, Abst. #3757. Oral Presentation. 37. El-Ashry, D., Miller, D.L., Yarden, R.I., Lorant, L.A., and Kern, F.G. Raf-Induced Estrogen-Independent Growth Results in Subsequent Loss of ER Expression. American Association for Cancer Research Meeting, San Diego, CA, 1997, Abst. #2907. Oral Presentation.


38. El-Ashry, D., Miller, D.L., Lippman, M.E., and Kern, F.G. Effects of Constitutive Raf-1 Kinase Expression on Estrogen Dependent Growth of Human Breast Cancer Cells. Endocrine Society Meeting, Washington, DC, 1995, Abst. #P2-647. Poster Presentation. 39. El-Ashry, D., Lippman, M.E., and Kern, F.G. Human TGF-α Contains an Estrogen Responsive Element Composed of Two Imperfect Palindromes. Keystone Symposia on Molecular and Cellular Biology (Positive Growth Control), Keystone, CO, 1992, Abst. #H513. Poster Presentation. 40. El-Ashry, D., Danielsen, M., Lippman, M.E., and Kern, F.G. Human Transforming Growth Factor-α Contains an Estrogen Responsive Element Comprised of Two Imperfect Palindromes. Endocrine Society Meeting, Washington, DC, 1991, Abst. #950. Poster Presentation. 41. El-Ashry, D., Lippman, M.E., and Kern, F.K. Human Transforming Growth Factor-α Contains an Estrogen Responsive Element Composed of Two Imperfect Palindromes. Sixth Annual Student Research Days, Georgetown University Medical Center, Washington, DC, 1991. Poster and Oral Presentation – won 2nd place in the Post-doctoral division. 42. Elashry-Stowers, D., Lawler-Heavner, J., and Edwards, D.P. Immunochemical Analysis of Human Progesterone Receptors Bound with the Progestin R5020 and the Anti-Progestin RU486. Endocrine Society Meeting, New Orleans, LA, 1988, Abst. #905. Oral Presentation. 43. Elashry-Stowers, D., and Edwards, D.P. Immunocytochemical Detection of Progesterone Receptors in Breast Cancer. American Association of Cancer Research Meeting, New Orleans, LA, 1988, Abst. #934. Oral Presentation. 44. El-Ashry, D., and Edwards, D.P. Immunocytochemical Localization of Progesterone Receptors in Breast Cancer with Monoclonal Anti-Receptor Antibodies. Endocrine Society Meeting, Indianapolis, IN, 1987, Abst. #181, p. 66. Poster Presentation. 45. El-Ashry, D., Toft, D.O., and Edwards, D.P. Immunocytochemical Localization of Progesterone Receptors in Human Breast Cancer Cells. 9th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1986, Vol. 8, Abst. #3, p. 79. Oral Presentation. 46. El-Ashry, D., Edwards, D.P., Dressler, L.G., and McGuire, W.L. Monoclonal Antibody Characterization of a Breast Cancer-Associated Antigen. 8th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1985, Vol. 6, Abst. #74. Oral Presentation. PROFESSIONAL RESEARCH SUPPORT (All amounts reflect direct costs) To be Submitted Role: PI Title: Role of MAPK miRNAs in Breast Cancer Progression and Metastasis Agency: NIH/NCI 1R01 CA178522-01-A1 Status: Pending % effort: 30% *Amount: $250,000 Start Date: 10/01/2014 End Date: 09/30/2019


Submitted Role: PI Title: “Indolent” vs “Aggressive” Cancer Activated/Associated Fibroblasts: Role in Breast Cancer Progression and Metastasis Agency: Women’s Health Association Status: Pending % effort: 3% *Amount: $50,000 Start Date: 10/01/2014 End Date: 09/30/2016 Role: PI Title: “Role of Indolent” vs “Aggressive” CAFs in Breast Cancer Progression and Metastasis: Establishment and Validation of Additional Cohorts of CAFs from “Indolent” vs “Aggressive” Human Breast Cancers Agency: Sylvester Tissue Bank Support Grant 2014 Status: Pending % effort: 5% *Amount: $20,000 Start Date: 10/01/2014 End Date: 09/30/2016 Current Role: co-PI (Lippman, PI) Title: The Role of MDSCs in Metastasis Agency: Breast Cancer Research Foundation Status: Active % effort: 20% *Amount: $240,000 Start Date: 10/01/2013 End Date: 09/30/2014 Past Role: co-I (Torrealabo, PI) Title: Breast Cancer Health Disparities: Mammary Fat Tissue and Tumor Macrophages Interplay Agency: NIH, NCI, R21 Status: Active % effort: 10% *Amount: $237,845 Start Date: 4/01/2011 End Date: 03/31/2013 (no-cost extension, 03/31/14 Role: PI Title: Restoring ER Expression and Anti-Estrogen Response in ER-Negative Breast Cancer Agency: Bankhead Coley Cancer Research Program RC1 (this was originally submitted to NIH as a Challenge grant and received the 5th%ile – ultimately funded through Bk-C) Status: Finished % effort: 20% *Amount: $581,423 Start Date: 10/01/2010 End Date: 09/30/2012 (with no-cost extension, 03/31/13) Role: Basic Science PI (Clinical PI is Anne Schott) Title: Evaluation of the Use of trastuzumab to induce increased ER expression in ER-negative/low, Her-2/neu positive breast cancer Agency: Drug company funded -- Genentech Status: Finished % effort: 15% *Amount: $144,672 Role: PI Title: Role of MAPK Regulated miRNAs in Regulating ER and p27 Expression Agency: Braman Family Breast Cancer Institute Development Grant Status: Finished % effort: 2% *Amount: $50,000


Start Date: 10/01/2011 End Date: 09/30/2012 Role: PI on Project 1, co-PI is Joyce Slingerland (PI of entire grant is Joyce Slingerland,) Title: Novel Experimental Therapeutic Approaches to Breast Cancer Therapy, Project 1: Use of MEK and Src inhibitors with fulvestrant in ER negative breast cancer Agency: Bankhead-Coley Cancer Research Program Status: Finished % effort: 10% *Amount: $1,000,000 (Project 1: $218,935) Start Date: 8/01/2009 End Date: 07/31/2012 Role: Principal Investigator Title: Mechanisms Underlying ER-Negative Breast Cancer Agency: NIH 1 R01 CA113674-02 Status: Inactive % effort: 50% *Amount: $925,000 Start Date: 07/01/2006 End Date: 06/30/2010 (with 1 yr no cost extension 6/30/2011) (received a priority score of 132, 0.6 percentile) Competitive renewal to be submitted 7/01/2012 Role: Principal Investigator Title: Restoring ER Expression and Anti-Estrogen Response to ER-Negative Breast Cancers Agency: Susan G. Komen Foundation BCTR0600890 Status: Finished % effort: 15% *Amount: $202,006 Start Date: 05/01/2006 End Date: 04/30/2008 Role: Principal Investigator Title: SWI/SNF: Mediator of the ER+/PR-, Tamoxifen-Resistant Phenotype? Agency: Susan G. Komen Foundation BCTR0403285 Status: Finished % effort: 20% *Amount: $199,725 Start Date: 05/01/2004 End Date: 04/30/2006 Role: Principal Investigator Title: Mechanisms Underlying the Acquisition of the ER-Negative Phenotype in Breast Cancer Agency: ACS RSG-01-033-01-TBE Status: Finished % effort: 40% *Amount: $625, 593 Start Date: 01/01/2001 End Date: 12/31/2004 (w/no cost ext- 12/31/2005) (this grant was ranked first in its study section out of a total of over 40 grants) Role: Principal Investigator Title: SWI/SNF: Mediator of the ER+/PR-, Tamoxifen-Resistant Phenotype in Breast Cancer? Agency: University of Michigan, Department of Internal Medicine Innovative Grants Program Status: Finished % effort: 10% *Amount: $40,000 Start Date: 01/01/2004 End Date: 12/31/2004 Role: Principal Investigator Title: Reversing the ER-Negative Phenotype in Breast Cancer Agency: Susan G. Komen Foundation BCTR2000 565 Status: Inactive % effort: 30% *Amount: $100,000 Start Date: 03/01/2001 End Date: 02/28/2002 (w/ no cost ext –09/30/03) Role: Principal Investigator Title: Raf-1 Induced Growth and Apoptosis in Breast Cancer Agency: NIH R29 – CA71465


Status: Finished % effort: 50% *Amount: $349,997 Start Date: 07/01/1996 End Date: 06/30/2001 Role: Co-Investigator (John Marshall, MD – PI) Title: PKC Modulation in Patients with Advanced Cancer Agency: NIH 1R01 – CA71856 Status: Finished % effort: 10% *Amount: $499,969 Start Date: 07/01/1996 End Date: 06/30/2000 (w/1 yr no cost ext –06/30/2001) Role: Principal Investigator Title: Role of Raf-1 Signaling in Breast Cancer – Progression to Estrogen-Independent Growth Agency: USAMRDC BAA for Breast Cancer Research, Career Development Award – DAMD17-94-J-4172 Status: Finished % effort: 80% *Amount: $185,184 Start Date: 06/15/1994 End Date: 07/14/1998 Role: Principal Investigator Title: Modulation of Estrogen Control of TGF-α Gene Expression Agency: Susan G. Komen Foundation Post-Doctoral Fellowship Status: Finished % effort: 80% *Amount: $90,000 Start Date: 10/01/1992 End Date: 09/30/1995 (Terminated 6/14/94 due to promotion to Research

Instructor) EDITORIAL RESPONSIBILITIES 2001 – present Member, Editorial Board. Cancer Biology and Therapy 2008 – present Member, Editorial Board, PloS ONE 2011 – present Scientific Editor, Senior Editorial Board, Endocrine-Related Cancer PROFESSIONAL AND HONORARY ORGANIZATIONS 1997 – present Member of American Association for Cancer Research and Women in Cancer

Research 1998-2001 Appointed for a 3-year term to the Research Affairs Committee of the Endocrine

Society.

1998 – present Member of Endocrine Society and Women in Endocrinology 2002 – 2008 Member of Central Society for Clinical Research HONORS AND AWARDS 1984 - 1987 NIH Predoctoral Fellowship, University of Colorado Health Sciences Center,

Denver, CO.


1985 - 1986 Recipient of $1000 Competitive Fellowship from the Graduate School of the

University of Colorado, Boulder, CO.

1986 – 1987 Vice President for Basic Science Graduate Student Council.

1987 Invited to attend Histopathology of Neoplasia Workshop hosted by the NCI and

UCLA Symposia, Keystone, CO

1989 Recipient of Chancellor's Award for Outstanding Basic Sciences for talk

presented at the Annual Student Research Symposium, University of Colorado Health Sciences Center, Denver, CO.

1991 Chosen as one of thirty-two finalists out of over 650 applicants for a Life Sciences

Research Award.

1991 Recipient of Second Place Postdoctoral Award for talk presented at Sixth Annual

Student Research Days, Georgetown University Medical Center, Washington, DC.

1992 Recipient of a Susan G. Komen Breast Cancer Foundation Postdoctoral

Fellowship.

2000 Co-Chair of Breast Cancer Mini-Symposium at Annual AACR Meeting, San

Francisco, CA.

2003 Chair of “Steroid and Nuclear Receptor/Growth Factor Signaling Pathways”

Mini-Symposium at Annual AACR Meeting, Washington, DC. 2007 Co-Chair of “Steroid Hormone Signaling, Coregulators and Crosstalk with

Growth Factor Pathways” Mini-Symposium at Annual AACR Meeting, Los Angelos, CA.

2010 Chair of “Novel Approaches to Elucidate Nuclear Receptor Function” Symposia

at the Annual Endocrine Meeting, San Diego, CA. 2013 AACR Annual Meeting – Organizing Committee – Endocrinology POSTDOCTORAL TRAINING Fellowship 02/89 – 06/94 Post-Doctoral Fellow. Lombardi Cancer Center, Washington, DC., Research area: Estrogen regulation of TGF-α in breast

cancer OTHER PROFESSIONAL ACTIVITIES


Review Service

Serve as a Reviewer for Molecular Endocrinology, Endocrinology, Journal of the National Cancer Institute, Oncogene, Breast Cancer Research and Treatment, Breast Cancer Research, Cancer Research, Clinical Cancer Research, Cancer Prevention Research, Molecular Cancer Research, Neoplasia, Journal of Biological Chemistry, Journal of Cellular Physiology, and Journal of Steroid Biochemistry and Molecular Biology

Ad-Hoc Member of NIH Tumor Cell Biology (TCB) Study Section, October 2014. Member of NIH R03/R21 Oncologic Sciences Study Section, March, 2014, July, 2014, and November, 2014. Member of Department of Defense, Army Breast Cancer Research Initiative Grant Review Study Sections — Experimental Therapeutics study section, November, 2013.

Ad-Hoc Member of NIH Study Section – R03/R21 Oncologic Sciences Section, November, 2013. Ad-Hoc Member of NIH Study Section – Tumor Cell Biology (TCB) Study Section, June 2013.

Reviewer for Breast Cancer Campaign (UK-based breast cancer charity), External Reviewer, April, 2013. Ad-Hoc Member of NIH Study Section – F30/F31/F32 Oncology Section, March 2013. Ad-Hoc Member of NIH Study Section – F30/F31/F32 Oncology Section, November 2012. Ad-Hoc Member of NIH Study Section – R03/R21 Oncologic Sciences Section, November, 2012. Ad-Hoc Member of NIH Study Section – Tumor Cell Biology (TCB) Study Section, June 2012. Member of Department of Defense, Army Breast Cancer Research Initiative Grant Review Study Sections — Various Pathobiology, Cell Biology, Endocrinology, and Molecular Biology study sections, 1996 - 2012. Member of Susan G. Komen for a Cure Career Catalyst Research Grant Review Board, 2011, 2012. Ad-Hoc Reviewer for the Dutch Cancer Society, 2011. Reviewer of abstracts submitted to the 91st and 92nd Annual Meeting of the Endocrine Society, ENDO 09 in the following categories: Growth Factor/Cytokine Signaling-Basic, Growth Factor/Cytokine Signaling-Translational, and Growth Factor/Cytokine Signaling-Clinical, January, 2009, 2010. Member of Susan G. Komen for a Cure Post-Doctoral Fellowship Grant Review Board, 2007-2010.


Member of Department of Defense, Army Prostate Cancer Research Initiative Grant Review Study Section — Various Pathobiology, Cell Biology, and Molecular Biology Study Sections, 1998 – 2006, 2010. Ad-Hoc Member of NIH Study Section – Tumor Cell Biology (TCB) Study Section, June, 2009. Reviewer for the Alberta Cancer Board of Edmonton – External Reviewer, June, 2007. Reviewer for the NIH UCC EARDA Pilot Grant Program, April 2007. Reviewer for Susan G. Komen Breast Cancer Foundation Focused Areas of Study Grant Program – Biomarker Identification and Validation, April 2007. Ad-Hoc Member of NIH Study Section – Drug Development and Molecular Pharmacology (DMP) Study Section, October, 2003. Member of Department of Defense, Army Ovarian Cancer Research Initiative Grant Review Study Sections — Ovarian Cancer 4, November, 2000. Member of California Breast Cancer Program Grant Review Study Section – Basic Biology, 1998 - 2000. Member of Department of Defense, Army Neurofibromatosis Research Initiative Grant Review Study Section — Basic Research 1, February, 1997. Served as an External Reviewer for the Large Project Intramural Grant Program at Allegheny University of the Health Sciences, January, 1997. Member of New Jersey Commission on Cancer Research Breast Cancer Research Fund Review Committee, April, 1996.

Extramural Invited Presentations “MAPK-Regulated microRNAs: Role in Breast Cancer” – Plenary Speaker at the University of Loyola Cancer Center First Annual Signaling Symposium, Chicago, IL, September 12, 2014. “MAPK miRNAs and the TME in Breast Cancer Progression” – Participant to the Breast Cancer Symposium Think Tank 24, Bonaire, January 16, 2014. “MAPK miRNAs: Role in Breast Cancer Progression and Metastasis” – Expedition Inspiration: The Role of Inflammation and Immunity in Breast Cancer Etiology and Treatment, February 15, 2013. “MAPK miRNAs in Breast Cancer Progression and Metastsis” – Participant to the Breast Cancer Symposium, Think Tank 23, Punta Cana, Dominican Republic, Jan 15, 2013. “MAPK and microRNAs in Breast Cancer” – Participant to the Breast Cancer Symposium, Think Tank 22, Playa del Carmen, MX, January 16, 2012. “The Role of MAPK in Breast Cancer” – Tulane University Cancer Center Grand Rounds, November 10, 2011.


“MAPK and the Biology Underlying ER-Negative Breast Cancer" – University of Illinois, Department of Molecular and Integrative Physiology Seminar Series, October, 20, 2011. “MAPK-Regulated miRNA Expression and Activity:Role in ER Negative Breast Cancer” -- University of Colorado Health Sciences Center, Hormone Related Malignancies Seminar Series, October 12, 2011. “MAPK and miRNAs in ER-Negative Breast Cancer” – Participant to the Breast Cancer Symposium, Think Tank 21, Jamaica, January 18, 2011. “MAPK and the Biology Underlying ER-Negative Breast Cancer” – Participant to the Breast Cancer Symposium, Think Tank 20, Barbados, January 22, 2010. “Impact of Altered Growth Factor Signaling on Estrogen Receptor Expression” – 7th International Symposium on Translational Research in Oncology, Huntington Beach, CA, October 17, 2008. “Role of Activated MAP Kinases in Estrogen Responsiveness of Breast Cancer” -- 2008 Endocrine Society Meeting, Symposium Session: “Integration of Signaling in Steroid Responsive Tumors”, San Francisco, CA, June 15-18, 2008. “Altered signal transduction pathways: Impact on ER signalling” -- 3rd Tenovus/AstraZeneca International Workshop on Growth Factor Signalling and Cancer Progression / Therapeutic Resistance in Breast Cancer, Cardiff, UK, May 1-2, 2008 “Updates on MAPK and the ER-Negative Phenotype” – Participant to the Breast Cancer Symposium, Think Tank 18, Kona, Hawaii, January 23, 2008. “ER-Negative Breast Cancer: New Thoughts on its Etiology and Therapy” – Department of Internal Medicine/Cell Biology Seminar Series, University of Miami – October 9, 2007. “ER-Negative Breast Cancer: Etiology and New Therapeutic Strategies” – Department of Cell and Cancer Biology, University of Cincinnati – September 20, 2007. “A Novel Therapy for ER-Negative Breast Cancer” – Expedition Inspiration, Sun Valley, Idaho, March 2007. “Understanding the Role of MAPK in Generation of the ER-Negative Phenotype: How Can We Move This Into the Clinic” -- Participant to the Breast Cancer Symposium, Think Tank 17, Cancun, Mexico, January 19, 2007. “Restoration of ER Expression and Anti-Estrogen Response in ER-Negative Breast Tumors: Strategies for Treatment and Prevention” – AACR, Fifth Annual AACR International Conference Frontiers in Cancer Prevention Research, Boston, MA, November 14, 2006. “Novel Therapeutics for ER-Negative Breast Cancer” – School of Medicine, Indiana University, March 27, 2006. “Reversal of the ER-Negative Phenotype and Restoration of Anti-Estrogen Response” – Participant to the Breast Cancer Symposium, Think Tank 16, Grand Cayman, January, 2006.


“Restoration of ER Expression and Anti-Estrogen Response to ER-Negative Breast Cancer” – American Cancer Society Mid-Lakes Division Annual Meeting, Notre Dame University, October, 2005. “Mechanisms Underlying MAPK-Mediated Repression of ERα in Breast Cancer” – Participant to the Breast Cancer Symposium, Think Tank 15, Curacao, January, 2005. "Mechanisms Underlying the Generation of the ERα-Negative Phenotype in Breast Cancer" – Department of Medicine, Cancer Center, University of Colorado Health Sciences Center, February, 2004. “The Role of Hyperactive MAPK in the Generation of the ERα Negative Breast Cancer Phenotype” – Department of Physiology, Wayne State University School of Medicine, April 2003.

“MAPK Substrates Mediating the ERα-Negative Phenotype Induced by Hyperactivation of MAPK” – Participant to the Breast Cancer Symposium, Think Tank 13, Aruba, January, 2003. “MAP(K)ing the Signaling Highways in Breast Cancer Progression” – Participant to the Breast Cancer Symposium, Think Tank 12, St. Maarten, Dutch Antilles, January, 2002. “Reversibility of the Estrogen Receptor-Negative Phenotype in Breast Cancer by Disruption of MAPK Signaling” -- Hematology/Oncology Research Conference, University of Alabama at Birmingham, February, 2001. “The Reversibility of the Estrogen Receptor-Negative Phenotype in Breast Cancer by Disruption of MAPK Signaling” – University of Michigan Comprehensive Cancer Center, Janurary, 2001. “The Role of Growth Factor Signaling in Repressing ER Expression” – Participant to the Breast Cancer Symposium, Think Tank 9, St. Thomas, January, 1999. “Constitutive Raf-1 Activity Results in MEK-Dependent Loss of ER Expression” – John Hopkins University Medical Center, April 28, 1998. “Raf-Induced Loss of ER Expression is Reversible: Is Redefinition of the ER-Negative Phenotype Needed?” – Participant to the Breast Cancer Symposium, Think Tank 8, Tobago, January 1998. “Effects of Constitutive Raf-1 Kinase Activity on Estrogen-Independent Growth” – Dept. of Cell Biology, Georgetown University Medical Center, October 23, 1997. “Raf-1 Mediated Estrogen-Independent Growth of Breast Cancer Cells” – Dept. of Pathology, University of Colorado Health Sciences Center, April 18, 1997. “Constitutive Raf-1 Activity Induces Both Estrogen-Independent Growth and Apoptosis of ER-Positive Breast Cancer Cells” – Duke University Breast Cancer SPORE Program and Medical Center, January 13, 1997. TEACHING


TEACHING SPECIALIZATION Courses and Lectures 2014 Lecture in Cancer BOMB course (April 22): Tumor Microenvironment. 2014 Director of CAB 615. 2013 PIBs 602: Cellular Interactions and Communication (October 24, 25). 2013 Lecture in Cancer BOMB course (April 25): Tumor Microenvironment. 2011 Director of CAB 615 (April, 2011), also presented lecture: Hormone Therapy and

Resistance in Breast Cancer in CAB 615. 2009 Co-presented a lecture with Dr. Marc Lippman on “ERK and ER in Breast Cancer” in the

“Scientific Reasoning and Logic in Cancer Biology: Bench to Bedside” course in the Cancer Biology Program (February 5 and 10, 2009).

2008 Presented a lecture on “Dissecting Signaling Pathways” in the “Approaches to

Understanding Cancer” course in the Cancer Biology Program (September 29, 2008). 2008 – present Member of Cancer Biology Program, University of Miami. 2007 – 2008 Member of Cellular and Molecular Biology Graduate Program, University of Michigan. 2004 - 2008 Presented a lecture on Hormone Action and Antagonists in the Basic Science Core

Curriculum for Hem/Onc Fellows (April 28, 2004; March 1, 2006, March 12, 2008). 2004 Presented a lecture on Sex Steroids in Pharmacology 660 (February 29, 2004). 2001 Developed and Directed a new course for the Tumor Biology Program – Clinical

Conference on Breast Cancer. 1999 - 2001 Developed and Co-directed a new course for the Tumor Biology Program – Pathologic

Basis of Cancer. 1997 - 2001 Served as organizer of the Translational Research Section for the Clinical Breast Cancer

Conference, and as organizer of the Signal Transduction Monthly meeting. 1997 - 2001 Tumor Biology – As a Core Faculty Member of the Interdisciplinary Tumor Biology

Program, presented 2 lectures on Hormones and Cancer, 1 lecture on Tyrosine Kinase Receptors and Signaling, and was Co-director of the weekly Student Data Seminar Series.

1997 - 2001 Member of Distinguished Problem Based Learning Facilitator Group – Facilitator in

small group, interactive format for all first year medical basic science courses. 1994 - 2001 Medical Oncology Fellows – Participated in weekly Clinical Breast Cancer Conference,

gave lectures on estrogen and progesterone receptors in breast cancer, and answered scientific/biological questions on hormone action.


1994 - 1996 Facilitator, Problem Based Learning: Biochemistry and Molecular Biology. Students Trained 2013 – present Mentor for Emilio Isso, UM undergraduate. 2013 Mentor for Lindsey Geeraerts – Lindsey is a medical school graduate who did not

match and wanted research experience for this year while trying for the 2014 match.

2012 – present Member and Chair of Graduate Student Thesis Committee – Ankita Thakar,

CAB, mentor is Tan Ince. 2012 – present Thesis mentor for Sanket Shah, CAB graduate student. 2012 – 2013 Mentor for Alana Steinberg, highschool student – accepted to Harvard for fall,

2014. 2010 – 2014 Thesis mentor for Amy Jayne Plotkin, MD/PhD, CAB graduate student. Amy

successfully defended her thesis July, 23, 2014 and has returned to medical school.

2010 – 2014 Mentor for Stephania Lairet, UM undergraduate – Stephania competed for and

was awarded a CAS Minorities and Women Summer Research Program fellowship for work in my lab. Stephania graduated in Dec 2013 and will attend Medical School Fall 2014.

2009 – 2014 Thesis mentor for Philip Miller, CAB graduate student – Phil successfully

achieved sufficiency in June, 2013 and successfully defended his thesis January 8, 2014.

2010 – 2013 Member and Chair of Graduate Student Thesis Committee – Stephanie Peacock,

CAB, mentor is Kerry Burnstein – Stephanie successfully defended her thesis in July, 2013.

2010 – 2013 Member of Graduate Student Thesis Committee – Linsey Lindley, Biochemistry

graduate student, mentor is Karoline Briegel – Linsey successfully defended her thesis in 2013.

2009 – 2012 Member, and Chair, of Graduate Student Thesis Committee – Anna-Marie Jegg,

CAB graduate student, mentor is Mark Pegram. Anna successfully defended her thesis in 12/2012.

2008 – 2009 Member of Graduate Student Thesis Committee – Adena Rosenblatt (mentor is

Kerry Burnstein). Adena successfully defended her thesis on June 24, 2009. 2007 – 2008 Mentor for Greg Lee, a first year Masters in Public Health graduate student.


3/2007 – 12/2007 Member of Graduate Student Thesis Committee – Sean Serraguard – Sean

successfully earned his Master’s degree from the Department of Pharmacology. 2006 – present Mentor for Prakash Vishnu, a resident at Wayne St., for his research elective, and

subsequent presentations of his work – his work is included in a just accepted manuscript, he was the presenter of an oral symposium talk at 2007 AACR and was the recipient of an AACR-AFLAC award for his abstract, and he won 1st place at the Wayne St. Medical Center Research Days for his presentation of this work. Prakash is doing his Hem/Onc fellowship at the Mayo Clinic.

9/2006 – 2008 Member of Mentoring Committee for Kathleen Diehl, MD, Dept of Surgery –

K08 5/2005 Member of Preliminary Exam Committee for Pharmacology Graduate Student –

Namandje Bumpus 3/2004 Member of Preliminary Exam Committee for Pharmacology Graduate Student –

Chris Evelyn 1/2003 – 2006 Member of Graduate Student Thesis Committee – Andrew Haas 2001 – present Student advisor to University of Michigan, Undergraduate Research Opportunity

Program (UROP) students. 2001 – 2005 Mentor for Shalini Murthy, Post-doctoral Fellow in my lab. 2000 - 2004 Thesis mentor for Jamie Holloway, Graduate Student, Tumor Biology Program,

Georgetown University. Jamie successfully defended her thesis in September of 2004.

2000 – 2001 Senior Thesis Advisor for Jennifer Lynch, Thomas Jefferson High School, VA.

Jen won 1st place in the Fairfax County Regional Science Fair for her project. 1998 - 2001 Thesis co-mentor and then full mentor for Michele Dougherty, Graduate Student,

Tumor Biology Program. Michele successfully defended her thesis in Sept. of 2001, was a Post-doctoral fellow in the laboratory of Deborah Morrison, NCI-Frederick until 2007 and was just promoted to a staff position.

1997 - 2000 Senior Thesis Advisor for Matthew Wolenski and Joe Alexander, Dept. of

Biology, Georgetown Unversity. 1998 - 1999 Senior Thesis Advisor for Anne Sawner, Thomas Jefferson High School, VA. 1998 Advisor for Richard Keating (medical student) and Ruba Dijani (high school

student) during summer. 1997 - 1998 Senior Thesis Advisor for Scott Thomas, Dept. of Biology, Georgetown

University.


1997 - 1998 Senior Thesis Advisor for Christina Twyman, Thomas Jefferson High School,

VA. Tina won 2nd place in the Fairfax County Regional Science Fair for her project.

1995 - 1996 Senior Thesis Advisor for Natalie Douglas, Robert E. Lee High School, VA. 1995 - 1996 Advisor for David Chism, Dept. of Biology, Georgetown University. SERVICE University of Miami 2014 Sylvester representative/panel speaker at the Bloomingdales Kickoff of Go Pink,

Give More, September 30, 2014. 2013 – present Member of PIBs Curriculum Committee as Cancer Biology Program

representative (alternate) 7/2008 – 6/2012 Member of PIBs Admissions and Outcomes Committee as Cancer Biology

Program representative. 7/2008 – present Alternate Member of Med IRB 9/2008 – present Faculty Reviewer, ACS Institutional Grant Review Committee 4/2009 – present Member of Cancer Biology Steering Committee 10/2011 – 4/2012 Member of Department of Medicine Faculty Peer Review Committee University of Michigan 10/2003 – 4/2008 Cancer Center Representative to ACS Fundraising activities – have spoken at the

Making Strides Against Breast Cancer Walk (10/03), Rallies and Kick-off Breakfasts (Ann Arbor, 8/07), and Thank You’s for Making Strides Against Breast Cancer Walk in Detroit – GM (4/06), Ann Arbor (9/06), and Detroit – GM (6/07), and Relay for Life Kick Offs in Brighton (02/04), Monroe (02/04), Local (05/04), and Hartland (9/06).

9/2006 Ambassador to the Second American Cancer Society's Celebration on the Hill in

Washington, D.C. The Celebration is to highlight the need for additional support for cancer research and to meet with legislators to make this point.

5/2006 – 3/2008 Member of the University of Michigan Institutional Review Board 10/2007 – 3/2008 Member of Univ. of Mich. Comprehensive Cancer Center Research Committee Georgetown University 1998 – 9/2001 Member of Research Computing Oversight Committee (Lombardi)


1999 – 9/2001 Member of Tissue Advisory Committee (Lombardi) 1/2001 – 9/2001 Member of Infrastructure Improvement Committee (Lombardi)


Documents

HIGHER EDUCATION EXPERIENCE Academic